Application of viable bacille Calmette-Guerin topically as a potential therapeutic modality in condylomata acuminata: A placebo-controlled study

Department of Andrology and Sexually Transmitted Diseases, Cairo University Hospital, Cairo, Egypt.
Urology (Impact Factor: 2.13). 03/2005; 65(2):247-50. DOI: 10.1016/j.urology.2004.09.025
Source: PubMed

ABSTRACT To evaluate the efficacy of topical application of viable bacille Calmette-Guérin (BCG) as a primary line of treatment in patients with condylomata acuminata.
We recruited 50 patients from the Department of Andrology and Sexually Transmitted Diseases, Cairo University Hospital complaining of genital warts. Patients were divided into two groups. Group 1 consisted of 25 patients who received BCG as a weekly topical treatment for 6 consecutive weeks. If still resistant, another intensive three-times-a-week course for 3 consecutive weeks was given. Group 2 consisted of 25 patients who received 0.9% saline solution as a placebo solution with the same procedure and follow-up as for group 1. All patients were followed up for 6 consecutive months. During the treatment course, the local response, wart state and size, and any side effects were reported.
A complete response with the disappearance of all condylomata acuminata was achieved in 20 (80%) of the 25 patients after a maximum of six BCG applications. Three patients (12%) needed another, more extensive, course, resulting in complete clearance 3 weeks later. Only 2 patients (8%) did not achieve a full response even after application of the intensified BCG course. No response was detected in the placebo group, with no improvement during follow-up. No recurrence developed in any responder. Minimal side effects, such as transient erythema and fever, were recorded during the study.
Topical BCG in the treatment of genital warts attained a high success rate in our study compared with the placebo solution, with insignificant side effects and no recurrence.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: 29 Türk Jinekolojik Onkoloji Dergisi 2009-2, Sayfa 29-34 Kondiloma aküminata di¤er ad›yla genital si¤iller, geliflmifl ülkel-erde en s›k görülen cinsel yolla bulaflan hastal›klardan biri olup prevalans› giderek artmaktad›r. Genital si¤illerin etkeni human papil-lomavirus (HPV)'dür ve viral aktivite enfekte kiflinin immün duru-muna göre de¤iflkenlik göstermektedir. Olgular›n %20 kadar›nda spontan regresyon gözlenebilmektedir. Tedavi modaliteleri topikal sitotoksik (bi/triklorasetik asit, podofilin, podofilotoksin, 5-flor-ourasil, yeflil çay ekstresi catechinler), immünoterapötik (imiquimod, interferon, Candida/kabakulak antijeni, BCG, oral inosiplex) ve ablatif/destrüktif cerrahi (kriyoterapi, lazer, elektrokoterizasyon, cer-rahi eksizyon) yöntemler olarak s›n›fland›r›labilir. Birçok tedavi yön-temi oldu¤undan hangi yöntemin kullan›laca¤›na karar verirken lezy-onun büyüklü¤ü, say›s›, lokalizasyonu, yayg›nl›¤› ve efllik eden durumlar (immünsupresyon, gebelik gibi) kadar hekimin ve hastan›n tercihi de belirleyici olmaktad›r. Oldukça genifl olan tedavi yöntemleri spektrumu içinde gerçekte hiçbir yöntem di¤erlerine üstün de¤ildir, ve tüm tedavi modaliteleri için de¤iflik oranlarda nüks bildirilmifltir, oran %30-70 olarak verilmektedir. Genital HPV enfeksiyonlar›n›n henüz radikal bir tedavisinin olmamas› ve serviks kanseri ile olan iliflkisi nedeniyle önleyici stratejiler önem kazanmaktad›r. Bunlardan birisi olan yeni afl› tedavileri ile enfeksiyonun engellenerek hastal›¤›n insidans›n›n›n azalaca¤› düflünülmektedir. Anahtar Kelimeler: Kondiloma aküminata, genital si¤iller, human papillomavirus (HPV), tedavi Condylomata acuminata, genital warts, are a common sexually transmitted disease in developed countries and its prevalance is increasing with time. Human papillomavirus (HPV) is the cause of genital warts and the viral activity depends on the immune status of the infected individual. Spontaneous regression of warts is seen in up to 20% of the cases. Various treatment modalities have been described which can be separated into topical cytotoxic (bi/trichloroacetic acid, podophyllin, podophyllotoxin, 5-fluorouracil, green tea catechins), immunomodulatory (imiquimod, interferon, Candida or mumps anti-gen, Bacillus Calmette-Guerin (BCG), oral inosiplex) and ablative/destructive surgery (cryotherapy, laser, electrocauterization, surgical excision). Multiple treatment approaches exist for the man-agement of genital warts, therefore treatment method decisions are based upon the number, size, extent and location of warts, co-existing medical conditions (e.g. immunodeficiency, pregnancy), and patient and physician preferences as well. Among such a large spectrum of treatment alternatives, no one therapeutic modality is superior to oth-ers and various recurrence rates have been reported for all of the methods, ranging between 30-70%. As there is currently no cure for HPV infection and a causal role for HPV infections in cervical cancer has been documented, preventive measures are increasingly impor-tant. New vaccine therapy for prevention of infection promise to reduce the incidence of disease.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cutaneous warts are known to be recurrent and often resistant to therapy. Resistant warts may reflect a localized or systemic cell mediated immune (CMI) deficiency to HPV. Many modalities of treatment are in use; most of the provider-administered therapies are destructive and cause scarring, such as cryotherapy, chemical cauterisation, curettage, electrodessication and laser removal. Most patient-applied agents like podophyllotoxin have the risk of application-site reactions and recurrence. Thus immunotherapy is a promising modality which could lead to resolution of warts without any physical changes or scarring and in addition would augment the host response against the causative agent, thereby leading to complete resolution and decreased recurrences. Immunomodulators can be administered systemically, intralesionally or intradermally, and topically. A few agents have been tried and studied extensively such as cimetidine and interferons; others are new on the horizon, such as Echinacea, green tea catechins and quadrivalent HPV vaccine, and their efficacy is yet to be completely established. Though some like levamisole have shown no efficacy as monotherapy and are now used only in combination, other more recent agents require large and long term randomized placebo-controlled trials to clearly establish their efficacy or lack of it. In this review, we focus on the immunomodulators that have been used for the treatment of warts and the studies that have been conducted on them.
    Indian Journal of Dermatology 03/2015; 60(2):118-129. DOI:10.4103/0019-5154.152502
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The Bacille Calmette-Guerin (BCG) vaccine is the only vaccine proved to be effective against tuberculosis and it remains the most commonly used vaccine worldwide. In addition to its effects on mycobacterial diseases, an increasing body of epidemiological evidence accumulated since its introduction in 1921 shows that BCG also exerts beneficial non-specific effects ranging from protection against non-mycobacterial diseases, decreased incidence of allergic diseases, and treatment of certain malignancies. The biological substrate of these effects is mediated partly by heterologous effects on adaptive immunity, but also on the potentiation of innate immune responses through epigenetic mechanisms, a process termed 'trained immunity'. The process of trained immunity may also play a role in the beneficial effects of BCG against tuberculosis and Mycobacterium tuberculosis infection, and this could have important consequences for our quest for improving vaccination strategies.
    Seminars in Immunology 10/2014; 26(6). DOI:10.1016/j.smim.2014.09.006 · 6.12 Impact Factor